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ABSTRACT 
This current research describes the eco-friendly synthesis of N-(s-phenyl)-3-phenyl-2-(phenyl sulfonamido) 
propanamides which are sulfonamide bearing diversified carboxamide moieties. The incorporation of amido 
functionality into the sulfonamide moieties was herein achieved in three steps in a cost-effective manner by starting 
from cheap amino acid, phenyl alanine which was reacted with benzenesulfonyl chloride to produce sulfonamide 
which upon subsequent esterification followed by amidation furnished carboxamido-incorporated sulfonamide 
analogs 9a-j in good to excellent yield. The completion of reaction processes was authenticated with Thin Layer 
Chromatography (TLC) and the chemical structures were validated through the elemental analysis result as well as 
spectroscopic means which include FT-IR, UV, 1H and 13C NMR. The technique used herein was found to be efficient 
and cost-effective for the production of the series of carboxamide diversified sulfonamide derivatives.   
Keywords: sulfonamide, spectroscopy, column chromatography, condensation, esterification.  
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INTRODUCTION 
Sulfonamides are the oldest and remain one of the commonly utilized antimicrobial therapeutics in 
veterinary medicine,1 broadly owing to cost-effectiveness and their relative efficacy in some common 
bacterial diseases.2 Sulfonamide are still widely used for conditions such as acne and urinary tract infections 
caused by bacteria resistant to other antibiotics.3 Sulfonamides constitute a privileged class among 
pharmacological agents by possessing properties including carbonic anhydrase enzyme (CA) inhibition, as 
well as diuretic, hypoglycemic, antibacterial, antiviral, and metalloprotease inhibitory effects.4 The 
discovery of valuable antimicrobial properties of azo dye called prontosil by Domagk's paved way for the 
identification of sulfanilamide as the first efficient agent in therapeutic research.5 The systematic review 
into the past work and usefulness of sulfonamides, unequivocally expresses that apart from the provision 
of earlier efficient treatment of pathogenic diseases,5,6 these class of compounds also unveiled 
unprecedented revolution in medicine7 for the new drug development.8 They are preferred due to the ease 
of administration,9 wide spectrum of antimicrobial activity,10 noninterference with the host defense 
mechanism and relative freedom from problems of super-infection.11 
The biological importance of sulfonamide derivatives is due to their structural resemblance to the naturally 
occurring p-aminobenzoic acid (PABA). The mechanism of action of sulfonamides is well understood to 
be via competitive inhibitory nature they conferred on p-aminobenzoic acid (PABA) thereby resulting in 
the disruption of the folic acid metabolic pathway and causing inhibition of multiplication of bacteria.12 
The structural similarity between sulfonamide and para-aminobenzoic acid (PABA) has led to the 
speculation that it might inhibit dihydropteroate synthase (DHPS) in the folate biosynthetic pathway and 
cause disruption in the synthesis of tetrahydrofolic acid which is a basic growth factor essential for the 
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metabolic process of bacteria.13 This allows them to interact with the biopolymers of the living system.14 
Some commercially available sulfonamide-based drugs that have done healing magic in the therapeutic 
world are the sulpha drugs 1-6 shown in Fig.-1. Apart from the already marketed drugs, there are many 
other sulfonamides that are being investigated currently for their promising activity against several 
malignancies. 
 
 
Fig.-1:  Selected Commercially available sulfonamide-based drugs 
 
In addition, sulfonamide motif contains a vital functionality owing to its numerous array of documented 
pharmacological properties which include antimalarial,15 antibacterial,16 anticancer,17 antioxidant,18 
antitubercular,19 anti-HIV,20 antitumor,21 anticonvulsant,22 antidepressant23 activities among others. 
Tolbutamide, the first sulfonylurea anti-diabetic drug, was approved in the United States in 1957 for the 
treatment of type 2 diabetics.24 Similarly, amido containing compounds were known to have highly 
enhanced pharmacological properties which include, but not limited to including antitubercular,25 analgesic, 
anti-inflammatory, insecticidal, antifungal and antitumor properties. The development of amide is a basic 
process of high importance in the study of organic compounds.26,27 Design of effective methodology for 
amide preparation stands as an excellent idea because of their significance in basic sciences, leading to 
many varieties of commercial and medicinal utilization and as crucial synthons in organic synthetic 
chemistry.26,28 
Therefore, it was envisaged that inserting of amide group into the sulfonamide moieties might lead to 
boosting or enhancement of antibacterial activity of such templates. Hence, it is conceivable to design the 
synthetic route in this present work in such a way to have amide functionality being incorporated within 
the framework of the synthesized sulfonamides. This might probably lead to the discovery of compounds 
with increased biological activity for future drug design and help in the comparative study of 
pharmacological properties of the ordinary sulfonamide to that of amide-bearing sulfonamide derivatives.    
 
EXPERIMENTAL 
All chemical compounds used were purchased from Sigma-Aldrich, USA and British Drug House 
Chemicals, UK. Solvents used were purified and dried by standard methods where necessary. Melting 
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points of solid compounds were established using Stuart melting point machine. The Infrared spectral data 
were determined with the aid of KBr pellet using the Perkin Elmer infrared Spectrophotometer and the 
frequencies of absorption were duly measured in wave number (cm-1) from 4000 cm-1 to 500 cm-1. The 
Ultraviolet-Visible (UV-vis.) spectral data were generated in either dichloromethane (CH2Cl2), or Dimethyl 
sulphoxide (DMSO) solvents using UV-Genesys Spectrophotometer. The absorbance was plotted against 
the wavelength λmax (nm) and the obtained molar absorptivity was used to calculate Log εmax. The reaction 
completion and degree of purity of the synthesized sulfonamide products were monitored by Thin Layer 
Chromatography. Furthermore, the 1H NMR and 13C NMR spectral analysis were carried out on NMR 
Bruker DPX 400 Spectrometer operating at the machine frequencies of 400 MHz and 100 MHz respectively 
using either CDCl3 or DMSO-d6, as a solvent for sample preparation prior to analyses. The standard 
abbreviation was used for the multiplicity. The acid value was confirmed with the aid of pH meter model 
PHB4. DHG-9023A Vacuum Oven was used to dry the solid where necessary while evaporation of the 
solvent was done using IKA® RV 10 Rotary evaporator. The determination of % composition of carbon, 
hydrogen, and nitrogen of the synthesized sulfonamides was carried out with Flash EA 1112 elemental 
analyzer. The result of % found of these elements was in concordance with that of % calculated values 
(Table-1). 
 
Synthesis  
Synthesis of 3-phenyl-2-(phenyl sulfonamide)propanoic acid, 7 
1.113 g of Na2CO3 was tipped into a mixture of phenylalanine (6.00 mmol, 0.83 g) and distilled water (6 
ml) with continuous stirring at room temperature till complete disappearance of the solute. The mixture 
placed in an ice bath until the temperature of 10 oC was attained; then followed by the addition of benzene 
sulfonyl chloride (6.00 mmol, 0.83 ml) batch-wisely three times for 1 h and warmed up to a room 
temperature also with stirring for 10 h. The reacting solution was worked upon. The first stage, the solution 
was poured into a separating funnel while the quantity of DCM was added to it, then it was shaking together 
for 15 mins and then allow to separate. The excess benzene sulfonyl chloride was collected into a 250 ml 
beaker while the expected product was collected into another big beaker for the better surface area. 
Secondly, the product collected into a big beaker was also worked upon by adding 2M HCl until pH of 2.1 
was reached and the sulfonamide crystallized out immediately. The product was filtered with a filter paper 
and spread on the beach to dry to afford 91% yieldo of 7. 1H-NMR (400 MHz, DMSOd6) δH: 7.61-7.59 (d, 
J = 8.28 Hz, 2H, Ar-H), 7.24-7.21 (m, 5H, Ar-H), 7.10-7.08 (m, 3H, Ar-H), 5.16-5.13 (d, J = 8.68 Hz, 1H, 
NH-CH), 4.21-4.17 (m, 1H, CH), 3.12-3.08 (dd, J1 = 5.48 Hz, J2 = 20.00 Hz, 1H, CH of CH2), 3.03-2.98 
(dd, J1 = 6.40 Hz, J2 = 20.00 Hz, 1H, CH of CH2). 13C-NMR (100 MHz, DMSOd6) δC: 178.1 (C=O), 143.9, 
136.6, 134.9, 129.8 (2 × CH), 129.6 (2 × CH), 128.8 (2 × CH), 127.4, 127.2 (2 × CH), 56.5 (CH), 39.0 
(CH2) ppm. IR (KBr) νmax/cm-1: 3435 (N-H), 3350 (OH), 3050 (C-H aromatic), 2925 (CH aliphatic), 2852 
(CH aliphatic), 1730 (C=O of COOH), 1605 (C=C), 1575 (C=N), 1375 (SO2, 1st band), 1225 (C=N), 1146 
(SO2, 2nd band), 1082 (C=N), 945 (=C-H), 724 (Ar-H).         
 
Synthesis of ethyl 3-phenyl-2-(phenylsulfonamido)propanoate, 8 
3-Phenyl-2-(phenylsulfonamido)propanoic acid 7 (6.55 mmol, 2.00 g) was tipped into 15 ml of absolute 
EtOH under continuous stirring at room temperature for about 15 mins, followed by the addition of 
concentrated H2SO4 (0.30 ml) drop-wisely and stirred at room temperature for additional 15 mins. The 
resulting solution was refluxed for 2 h and the solvent was evaporated to dryness with rotary evaporator. 
The resulting solid was triturated with cold water. It was filtered and air-dried to obtain 3-phenyl-2-
(phenylsulfonamido)propanoate, 8 in 66% yield. 1H-NMR (400 MHz, DMSOd6) δH: 7.63-7.61 (d, J = 8.32 
Hz, 2H, Ar-H), 7.25-7.18 (m, 5H, Ar-H), 7.13-7.10 (m, 3H, Ar-H), 5.88-5.86 (d, J = 9.44 Hz, 1H, NH-CH), 
4.31-4.25 (m, 1H, CH), 3.13-3.09 (dd, J1 = 5.48 Hz, J2  = 20.00 Hz, 1H, CH of CH2), 3.04-2.99 (dd, J1 = 
6.40 Hz, J2  = 20.00 Hz, 1H, CH of CH2), 2.79-2.74 (q, J = 7.12 Hz, 2H, CH2-CH3), 0.88-0.84 (t, J = 7.12 
Hz, 3H, CH3-CH2). 13C-NMR (100 MHz, DMSOd6) δC: 175.7 (C=O), 143.1, 136.6, 134.8, 129.9 (2 × CH), 
129.5 (2 × CH), 128.8 (2 × CH), 127.5, 127.1 (2 × CH), 56.7 (CH), 42.5 (CH2), 39.3 (CH2), 19.2 (CH3) 
ppm. IR (KBr) νmax/cm-1: 3435 (N-H), 3042 (C-H aromatic), 2925 (CH aliphatic), 2852 (CH aliphatic), 
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1745 (C=O of ester), 1605 (C=C), 1574 (C=N), 1452 (CH2 deformation), 1377 (SO2, 1st band), 1225 (C=N), 
1146 (SO2, 2nd band), 1082 (C-N), 946 (=C-H), 725 (Ar-H).    
 
General procedure for synthesis of targeted sulfonamide derivatives, 9a-j 
Ethyl 3-phenyl-2-(phenyl sulfonamide)propanoate, 8 (3.30 mmol, 1.00 g), was transferred into 250 ml 
quick fit flask containing absolute EtOH (15 ml); then the resulting solution was allowed to stir at ambient 
temperature for 15 mins. The corresponding amino-containing nucleophile (3.30 mmol) was weighed and 
transferred into the solution and stirred for extra 15 mins at the same ambient condition. The reacting 
solution was then refluxed for 2 h and the solvent was evaporated to afford crude solids which were 
recrystallized from methanol to furnish the corresponding amido-bearing sulfonamide motifs 9a-j in 
varying yields.  
 
Synthesis of N,3-diphenyl-2-(phenyl sulfonamide)propanamide, 9a  
Reactive intermediate 8 (3.30 mmol, 1.00 g) reacted with aniline (3.30 mmol, 0.30 ml) to afford N,3-
diphenyl-2-(phenylsulfonamido)propanamide, 9a in 86% yield. 1H-NMR (400 MHz, DMSOd6) δH: 11.08 
(s, 1H, NH-CO), 7.62-7.60 (d, J = 8.34 Hz, 2H, Ar-H), 7.45-7.43 (d, J = 8.00 Hz, 2H, Ar-H), 7.27-7.24 (m, 
5H, Ar-H), 7.20-7.18 (m, 3H, Ar-H), 7.15-7.12 (m, 3H, Ar-H), 5.88-5.86 (d, J = 9.42 Hz, 1H, NH-CH), 
4.31-4.25 (m, 1H, CH), 3.13-3.09 (dd, J1 = 5.48 Hz, J2  = 20.00 Hz, 1H, CH of CH2), 3.04-2.99 (dd, J1 = 
6.40 Hz, J2  = 20.00 Hz, 1H, CH of CH2). 13C-NMR (100 MHz, DMSOd6) δC: 171.3 (C=O), 145.1, 143.8, 
136.7, 134.9, 130.2 (2 × CH), 129.8 (2 × CH), 129.6 (2 × CH), 128.8 (2 × CH), 127.4, 127.2 (2 × CH), 
119.1, 115.2 (2 × CH), 56.5 (CH), 39.0 (CH2) ppm. IR (KBr) νmax/cm-1: 3415 (N-H), 2930 (C-H aliphatic), 
2850 (C-H aliphatic), 1685 (C=O), 1610 (C=C aromatic), 1491 (N-H amide), 1459 (CH2 deformation), 
1377 (SO2, 1st band), 1140 (SO2, 2nd band), 1073 (C-N), 952 (=C-H), 848 (C=C out of plane bending), 743 
(Ar-H, bending and ring puckering). λmax /nm (log εmax): 207 (5.01), 244 (5.47), 286 (5.11), 583 (2.00). 
 
Synthesis of N-(3-nitrophenyl)-3-phenyl-2-(phenylsulfonamido)propanamide, 9b  
Reactive intermediate 8 (3.30 mmol, 1.00 g) reacted with 3-nitroaniline (3.30 mmol, 0.45 g) to afford N-
(3-nitrophenyl)-3-phenyl-2-(phenylsulfonamido) propanamide, 9b in 87% yield. 1H-NMR (400 MHz, 
DMSOd6) δH: 11.10 (s, 1H, NH-CO), 8.01 (s, 1H, Ar-H), 7.62-7.60 (d, J = 8.34 Hz, 2H, Ar-H), 7.47-7.46 
(d, J = 6.20 Hz, 1H, Ar-H), 7.27-7.24 (m, 5H, Ar-H), 7.20-7.18 (m, 3H, Ar-H), 7.14-7.12 (m, 2H, Ar-H), 
5.87-5.84 (d, J = 9.04 Hz, 1H, NH-CH), 4.31-4.25 (m, 1H, CH), 3.14-3.10 (dd, J1 = 5.86 Hz, J2  = 20.00 
Hz, 1H, CH of CH2), 3.04-2.99 (dd, J1 = 6.44 Hz, J2  = 20.00 Hz, 1H, CH of CH2). 13C-NMR (100 MHz, 
DMSOd6) δC: 171.3 (C=O), 145.1, 144.2, 143.8, 136.7, 134.9, 130.2 (2 × CH), 129.8 (2 × CH), 129.6 (2 × 
CH), 128.8 (2 × CH), 127.4, 127.2 (2 × CH), 119.1, 115.3, 56.4 (CH), 39.1 (CH2) ppm. IR (KBr) νmax/cm-
1: 3422 (N-H), 3029 (C-H aromatic), 2923 (C-H aliphatic), 2853 (C-H aliphatic), 1685 (C=O amide), 1600 
(C=C aromatic), 1579 (C=N), 1459 (CH2 deformation), 1420 (CH2 deformation), 1377 (SO2, 1st band), 
1352 (N=O stretching),  1228 (C-N), 1127 (SO2, 1st band), 921 (=C-H), 735 (Ar-H). λmax /nm (log εmax): 206 
(4.72), 227 (4.20), 251 (3.99), 374 (4.23). 
    
Synthesis of N-(4-chlorophenyl)-3-phenyl-2-(phenylsulfonamido)propanamide, 9c  
Reactive intermediate 8 (3.30 mmol, 1.00 g) reacted with 4-chloroaniline (3.30 mmol, 0.42 g) to afford N-
(4-chlorophenyl)-3-phenyl-2-(phenylsulfonamido)propanamide, 9c in 74% yield. 1H-NMR (400 MHz, 
DMSOd6) δH: 11.04 (s, 1H, NH-CO), 7.62-7.60 (d, J = 8.26 Hz, 2H, Ar-H), 7.42-7.40 (d, J = 8.00 Hz, 2H, 
Ar-H), 7.25-7.21 (m, 5H, Ar-H), 7.16-7.14 (d, J = 8.12 Hz, 2H, Ar-H), 7.10-7.07 (m, 3H, Ar-H), 5.16-5.14 
(d, J = 7.68 Hz, 1H, NH-CH), 4.20-4.17 (m, 1H, CH), 3.12-3.07 (dd, J1 = 6.02 Hz, J2  = 20.00 Hz, 1H, CH 
of CH2), 3.03-2.98 (dd, J1 = 6.40 Hz, J2  = 20.00 Hz, 1H, CH of CH2). 13C-NMR (100 MHz, DMSOd6) δC: 
171.3 (C=O), 145.1, 143.9, 142.7, 136.6, 134.9, 129.8 (2 × CH), 129.6 (2 × CH), 128.8 (2 × CH), 127.4, 
127.2 (2 × CH), 123.7 (2 × CH), 115.2 (2 × CH), 56.7 (CH), 39.2 (CH2) ppm. IR (KBr) νmax/cm-1: 3350 (N-
H, 2o amine), 3100 (C-H aromatic), 2925 (C-H aliphatic), 2852 (C-H aliphatic), 1685 (C=O amide), 1620 
(C=C aromatic), 1599 (C=N), 1496 (CH2, deformation), 1377 (SO2, 1st band), 1220 (C=N), 1130 (SO2 2nd 
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band), 1074 (C-N), 745 (Ar-H), 698 (C-Cl bending). λmax /nm (log εmax): 207 (4.71), 251 (3.70), 269 (3.64), 
323 (4.14). 
 
Synthesis of N-(naphthalen-1-yl)-3-phenyl-2-(phenylsulfonamido)propanamide, 9d  
Reactive intermediate 8 (3.30 mmol, 1.00 g) reacted with α-naphthylamine (3.30 mmol, 0.47 g) to afford 
N-(naphthalen-1-yl)-3-phenyl-2-(phenylsulfonamido)propanamide, 9d in 65% yield. 1H-NMR (400 MHz, 
DMSOd6) δH: 11.05 (s, 1H, NH-CO), 8.16-8.14 (d, J = 7.24 Hz, 1H, Ar-H), 8.04-8.02 (d, J = 7.66 Hz, 1H, 
Ar-H), 7.61-7.59 (d, J = 8.28 Hz, 2H, Ar-H), 7.57-7.53 (m, 3H, Ar-H), 733-7.32 (d, J = 7.04 Hz, 1H, Ar-
H), 7.24-7.21 (m, 5H, Ar-H), 7.17-7.15 (d, J = 7.14 Hz, 1H, Ar-H), 7.10-7.08 (m, 3H, Ar-H), 5.16-5.13 (d, 
J = 8.68 Hz, 1H, NH-CH), 4.21-4.18 (m, 1H, CH), 3.11-3.08 (dd, J1 = 5.50 Hz, J2  = 20.00 Hz, 1H, CH of 
CH2), 3.02-2.98 (dd, J1 = 6.38 Hz, J2  = 20.00 Hz, 1H, CH of CH2). 13C-NMR (100 MHz, DMSOd6) δC: 
171.0 (C=O), 145.3, 143.1, 139.8, 136.6, 134.8, 133.2, 132.4, 130.1, 129.9 (2 × CH), 129.5 (2 × CH), 128.8 
(2 × CH), 127.5, 127.1 (2 × CH), 125.7, 123.4, 119.9, 119.2, 115.2, 56.7 (CH), 39.3 (CH2) ppm. IR (KBr) 
νmax/cm-1: 3400(N-H), 3045 (CH aromatic), 2924 (CH aliphatic), 2854 (C-H aliphatic), 1605 (C=C 
aromatic), 1555 (C=N), 1511 (N-H 2o amine), 1461 (CH2 deformation), 1377 (SO2 1st band), 1216 (C=N), 
1130 (SO2 2nd band), 1073 (C-N), 912 (=C-H), 766 (Ar-H). λmax /nm (log εmax): 209 (4.69), 269 (4.16), 332 
(5.43), 578 (3.23). 
 
Synthesis of N-(1-hydrazinyl-1-oxo-3-phenylpropane-2-yl) benzenesulfonamide, 9e  
Reactive intermediate 8 (3.30 mmol, 1.00 g) reacted with hydrazine hydrate (3.30 mmol, 0.16 ml) to afford 
N-(1-hydrazinyl-1-oxo-3-phenylpropan-2-yl)benzenesulfonamide, 9e in 54% yield. 1H-NMR (400 MHz, 
DMSOd6) δH: 11.00 (s, 1H, NH-CO), 7.62-7.60 (d, J = 8.32 Hz, 2H, Ar-H), 7.24-7.21 (m, 5H, Ar-H), 7.10-
7.08 (m, 3H, Ar-H), 5.40 (s, 2H, NH2), 5.14-5.11 (d, J = 8.60 Hz, 1H, NH-CH), 4.20-4.17 (m, 1H, CH), 
3.13-3.08 (dd, J1 = 5.82 Hz, J2  = 20.00 Hz, 1H, CH of CH2), 3.02-2.97 (dd, J1 = 6.44 Hz, J2  = 20.00 Hz, 
1H, CH of CH2). 13C-NMR (100 MHz, DMSOd6) δC: 172.1 (C=O), 143.9, 136.3, 134.7, 129.9 (2 × CH), 
129.4 (2 × CH), 128.8 (2 × CH), 127.4, 127.1 (2 × CH), 56.4 (CH), 39.1 (CH2) ppm. IR (KBr) νmax/cm-1: 
3450 (N-H), 3100 (CH aromatic), 2924, 2854 (C-H aliphatic), 1627 (C=C aromatic), 1560 (C=N), 1459 
(CH2 deformation), 1377 (SO2 1st band), 1226 (C=N), 1129 (SO2 2nd band), 1074 (C-N), 913 (=C-H), 746 
(Ar-H). λmax /nm (log εmax): 206 (4.57), 242 (4.33), 545 (4.32), 584 (4.34). 
 
Synthesis of N-(1-(2-(2,4-dinitrophenyl)hydrazinyl)-1-oxo-3-phenylpropan-2-yl)benzene 
sulfonamide, 9f  
Reactive intermediate 8 (3.30 mmol, 1.00 g) reacted with 2,4-dinitrophenylhydrazine (3.30 mmol, 0.65 g) 
to afford N-(1-(2-(2,4-dinitrophenyl)hydrazinyl)-1-oxo-3-phenylpropan-2-yl) benzene sulfonamide, 9f in 
82% yield. 1H-NMR (400 MHz, DMSOd6) δH: 11.05 (s, 1H, NH-CO), 10.00 (s, 1H, NH), 8.82 (s, 1H, Ar-
H), 828-8.25 (d, J = 12.36 Hz, 1H, Ar-H), 7.69-7.66 (d, J = 9.72 Hz, 1H, Ar-H), 7.31-7.25 (m, 6H, Ar-H), 
7.00 (s, 5H, Ar-H), 5.20 (s, 1H, NH), 3.92 (m, 1H, CH), 3.12-3.07 (dd, J1 = 6.02 Hz, J2  = 20.00 Hz, 1H, 
CH of CH2), 3.03-2.98 (dd, J1 = 6.40 Hz, J2  = 20.00 Hz, 1H, CH of CH2). 13C-NMR (100 MHz, DMSOd6) 
δC: 171.3 (C=O), 143.1, 141.7, 139.7, 139.1, 136.6, 134.8, 129.9 (2 × CH), 129.3 (2 × CH), 128.7 (2 × CH), 
127.5, 127.1 (2 × CH), 125.7, 123.2, 119.6, 56.8 (CH), 39.1 (CH2) ppm. IR (KBr) νmax/cm-1: 3367 (N-H), 
2924 (C-H of CH2), 1676 (C=O of amide), 1601 (C=C), 1489 (CH2 deformation), 1376 (SO2), 1182 (SO2, 
2nd band), 1092 (C-N), 980 (=C-H) 747 (Ar-H). λmax /nm (log εmax): 209 (4.83), 254 (4.73), 278 (4.75), 362 
(5.46). 
 
Synthesis of 2-(3-phenyl-2-(phenyl sulfonamide)propanoyl)hydrazinecarboxamide, 9g  
Reactive intermediate 8 (3.30 mmol, 1.00 g) reacted with semicarbazide (3.30 mmol, 0.25 g) to afford 2-
(3-phenyl-2-(phenylsulfonamido)propanoyl)hydrazinecarboxamide, 9g in 55% yield. 1H-NMR (400 MHz, 
DMSOd6) δH: 11.05 (s, 1H, NH-CO), 10.54 (s, 1H, NH), 8.41 (s, 1H, NH of NH2), 7.95 (s, 1H, NH of NH2), 
7.61-7.59 (d, J = 8.30 Hz, 2H, Ar-H), 7.24-7.20 (m, 5H, Ar-H), 7.11-7.08 (m, 3H, Ar-H), 5.13-5.11 (d, J = 
7.86 Hz, 1H, NH-CH), 4.20-4.16 (m, 1H, CH), 3.13-3.08 (dd, J1 = 5.82 Hz, J2  = 20.00 Hz, 1H, CH of CH2), 
3.02-2.98 (dd, J1 = 6.40 Hz, J2  = 20.00 Hz, 1H, CH of CH2). 13C-NMR (100 MHz, DMSOd6) δC: 172.9 
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(C=O), 172.1 (C=O), 143.9, 136.3, 134.7, 129.9 (2 × CH), 129.4 (2 × CH), 128.8 (2 × CH), 127.4, 127.1 
(2 × CH), 56.2 (CH), 39.4 (CH2) ppm. IR (KBr) νmax/cm-1: 3422, 3419 (NH2, 2 bands), 3367 (N-H), 3035 
(CH aromatic), 2928 (C-H of CH2), 1687 (C=O of amide), 1676 (C=O of amide), 1615 (C=C), 1575 (C=N), 
1485 (CH2 deformation), 1375 (SO2), 1175 (SO2, 2nd band), 1095 (C-N), 965 (=C-H), 745 (Ar-H). λmax /nm 
(log εmax): 212 (4.73), 230 (3.68), 251 (3.92), 329 (3.59). 
 
Synthesis of N-pentyl-3-phenyl-2-(phenylsulfonamido)propanamide, 9h  
Reactive intermediate 8 (3.30 mmol, 1.00 g) reacted with n-pentylamine (3.30 mmol, 0.43 ml) to afford N-
pentyl-3-phenyl-2-(phenylsulfonamido)propanamide, 9h in 89% yield. 1H-NMR (400 MHz, DMSOd6) δH: 
7.61-7.59 (d, J = 8.28 Hz, 2H, Ar-H), 7.24-7.21 (m, 5H, Ar-H), 7.10-7.08 (m, 3H, Ar-H), 5.89-5.87 (d, J = 
8.88 Hz, 1H, NH-CH), 4.30-4.26 (m, 1H, CH), 3.44-3.43 (t, J = 3.28 Hz, 2H, NCH2CH2), 1.96-1.93 (m, 
4H, 2 × CH2), 1.49-1.46 (m, 2H, CH2), 3.12-3.08 (dd, J1 = 5.48 Hz, J2  = 20.00 Hz, 1H, CH of CH2), 3.03-
2.98 (dd, J1 = 6.40 Hz, J2  = 20.00 Hz, 1H, CH of CH2), 0.90-0.88 (t, J = 3.96 Hz, 2H, CH3CH2). 13C-NMR 
(100 MHz, DMSOd6) δC: 171.7 (C=O), 143.8, 136.6, 134.9, 129.9 (2 × CH), 129.6 (2 × CH), 128.7 (2 × 
CH), 127.4, 127.2 (2 × CH), 56.4 (CH), 39.1 (CH2), 30.3 (CH2), 23.8 (CH2), 23.5 (CH2), 22.9 (CH2), 18.6 
(CH3) ppm. IR (KBr) νmax/cm-1: 3367 (N-H), 3044 (CH aromatic), 2922 (C-H of CH2), 1685 (C=O of 
amide), 1620 (C=C), 1575 (C=N), 1460 (CH2 deformation), 1377 (SO2, 1st band), 1178 (SO2, 2nd band), 
1089 (C-N), 943 (=C-H), 725 (Ar-H). λmax /nm (log εmax): 212 (4.87), 548 (4.57), 575 (4.53), 593 (4.54). 
 
Synthesis of N-cyclohexyl-3-phenyl-2-(phenylsulfonamido)propanamide, 9i  
Reactive intermediate 8 (3.30 mmol, 1.00 g) reacted with cyclohexylamine (3.30 mmol, 0.33 g) to afford 
N-cyclohexyl-3-phenyl-2-(phenylsulfonamido)propanamide, 9i in 63% yield. 1H-NMR (400 MHz, 
DMSOd6) δH: 7.62-7.59 (d, J = 8.68 Hz, 2H, Ar-H), 7.25-7.21 (m, 5H, Ar-H), 7.11-7.08 (m, 3H, Ar-H), 
5.88-5.86 (d, J = 8.16 Hz, 1H, NH-CH), 4.30-4.26 (m, 1H, CH), 4.21-4.18 (quintet, J = 5.68 Hz, 1H, 
CH(CH2)2) 3.44-3.42 (t, J = 3.68 Hz, 2H, NCH2CH2), 3.12-3.08 (dd, J1 = 5.48 Hz, J2  = 20.00 Hz, 1H, CH 
of CH2), 3.03-2.98 (dd, J1 = 6.40 Hz, J2  = 20.00 Hz, 1H, CH of CH2), 1.61-1.58 (m, 4H, 2 × CH2), 1.49-
1.46 (m, 4H, 2 × CH2), 1.20-1.17 (m, 2H, CH2). 13C-NMR (100 MHz, DMSOd6) δC: 171.7 (C=O), 143.8, 
136.6, 134.9, 129.9 (2 × CH), 129.6 (2 × CH), 128.7 (2 × CH), 127.4, 127.2 (2 × CH), 56.4 (CH), 39.1 
(CH2), 30.3 (CH2), 23.8 (CH2), 23.5 (CH2), 22.9 (CH2), 18.6 (CH3) ppm. IR (KBr) νmax/cm-1: 3365 (N-H), 
3040 (CH aromatic), 2928 (C-H of CH2), 1685 (C=O of amide), 1620 (C=C), 1575 (C=N), 1460 (CH2 
deformation), 1377 (SO2, 1st band), 1175 (SO2, 2nd band), 1090 (C-N), 943 (=C-H), 721 (Ar-H). λmax /nm 
(log εmax): 221 (5.43), 260 (5.44), 578 (3.80), 584 (3.80).    
 
Synthesis of N-hexadecyl-3-phenyl-2-(phenylsulfonamido)propanamide, 9j  
Reactive intermediate 8 (3.30 mmol, 1.00 g) reacted with hexadecylamine (3.30 mmol, 0.79 g) to afford N-
hexadecyl-3-phenyl-2-(phenylsulfonamido)propanamide, 9j in 91% yield. 1H-NMR (400 MHz, DMSOd6) 
δH: 7.61-7.59 (d, J = 8.28 Hz, 2H, Ar-H), 7.24-7.21 (m, 5H, Ar-H), 7.10-7.08 (m, 3H, Ar-H), 5.89-5.87 (d, 
J = 8.88 Hz, 1H, NH-CH), 4.30-4.26 (m, 1H, CH), 3.46-3.45 (t, J = 3.06 Hz, 2H, NCH2CH2), 3.12-3.08 
(dd, J1 = 5.48 Hz, J2  = 20.00 Hz, 1H, CH of CH2), 3.03-2.98 (dd, J1 = 6.40 Hz, J2  = 20.00 Hz, 1H, CH of 
CH2), 1.54-1.51 (m, 2H, CH2), 1.46-1.1.42 (m, 2H, CH2), 1.29-1.20 (m, 24H, 12 × CH2), 0.90-0.87 (t, J = 
4.22 Hz, 2H, CH3CH2). 13C-NMR (100 MHz, DMSOd6) δC: 171.7 (C=O), 143.8, 136.6, 134.9, 129.9 (2 × 
CH), 129.6 (2 × CH), 128.7 (2 × CH), 127.4, 127.2 (2 × CH), 56.4 (CH), 39.9 (CH2), 39.1 (CH2), 30.3 
(CH2), 29.7 (8 × CH2), 29.1 (2 × CH2), 26.7 (CH2), 23.5 (CH2), 22.9 (CH2), 15.9 (CH3) ppm. IR (KBr) 
νmax/cm-1: 3367 (N-H), 3044 (CH aromatic), 2922 (CH aliphatic), 2848 (CH aliphatic), 1687 (C=O of 
amide), 1615 (C=C), 1575 (C=N), 1460 (CH2 deformation), 1376 (SO2, 1st band), 1175 (SO2, 2nd band), 
1093 (C-N), 943 (=C-H), 725 (Ar-H). λmax /nm (log εmax): 212 (5.12), 265 (5.23), 378 (4.89), 545 (3.80).  
 
RESULTS AND DISCUSSION 
In the continuation of the research endeavor to design and derived more bioactive sulfonamide 
frameworks,12,29 we have herein reported the synthesis of functionalized carboxamide-based sulfonamide 
derivatives via a facile synthetic route. Synthesis of the precursor 7, reactive intermediate 8 and the targeted 
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carboxamide-based sulfonamide final products 9a-j were accomplished according to the steps illustrated in 
Schemes 1, 2 and 3 respectively. The synthesis began with the reaction of benzenesulfonyl chloride with 
L-phenyl alanine in the presence of sodium carbonate solution at ambient temperature for 10 h to afford 3-
phenyl-2-(phenyl sulfonamido) propanoic acid, 7 (Scheme 1). This was achieved in excellent yield via our 
earlier reported method.29 Secondly, the precursor 1 was esterified with absolute ethanol for 2 h in the 
presence of a mineral acid catalyst to afford ethyl 3-phenyl-2-(phenyl sulfonamide)propanoate, 8 (Scheme 
2). The reaction of reactive intermediate sulfonamide 8 with aniline derivatives a-c via refluxing in the 
presence of ethanol afforded compounds 9a-c, while the treatment of the compound 8 with α-naphthylamine 
d furnished compound 9d. When the reactive sulfonamide 8 was heated under reflux in the presence of 
hydrazine hydrate e, 2,4-dinitrophenylhydrazine f and semicarbazide g, the corresponding sulfonamide-
based hydrazine carboxamide 9e-g were obtained in varying yields as shown in Table 1. Finally, the thermal 
reaction of 8 with three aliphatic amines n-pentylamine h, cyclohexylamine i and hexadecylamine j, over 
2 h of refluxing provided a convenient route to access the corresponding sulfonamides 9h-j. The synthetic 
route for accessing all the final titled products 9a-j is as shown in Scheme 3.        
 
 
Scheme-1: Pathway for the synthesis of 3-phenyl-2-(phenyl sulfonamide)propanoic acid, 7 
 
 
Scheme-2: Pathway for the synthesis of ethyl 3-phenyl-2-(phenyl sulfonamide)propanoate, 8 
 
Scheme-3: Synthetic route to N-substituted-3-phenyl-2-(phenylsulfonamido)propanamide, 9a-j 
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The result of the physicochemical parameter which includes molecular formula, melting point, yield, Rf, 
and color and elemental analysis was herein reported (Table-1). The final products’ molecular formula 
varied from 305.35 for compound 9a to 528.79 for 9j. All the synthesized compounds had definite melting 
points except compound 9h alone which was not determined because of its semi-solid nature at room 
temperature. The melting point of all the compounds was high, with 9b having lowest at the value of 173-
175 oC and 7 having the highest value of 296-298 oC. These high melting point values might be attributable 
to the amide bond formation and the tendency for hydrogen bond existence therein. The percentage yields 
of targeted compounds ranged from good to excellent in nature. Coincidentally, the first (precursor 7) and 
the last compound (sulfonamide 9j) had the same yield of 91% which was the highest yield recorded herein 
while targeted compound 9e had the lowest yield (55%) among the series. The Thin Layer Chromatography 
(TLC) was used to monitor the progress and completion of the reaction as well as to ascertain the purity 
level of the compounds synthesized. The Rf calculated from the TLC varied from 0.44 for precursor 7 to 
0.87 for sulfonamide 9d. Although, three different solvent ratio combination were used as eluents, the 
precursor 7 exhibiting lowest Rf was an indication of high polarity due to the presence of COOH in 7. This 
further corroborated the highest melting point observed in precursor 7 among all the compound synthesized 
herein. This behavior in precursor 7 might be as a result of the existence of stronger intramolecular hydrogen 
bonding in COOH than in the amide formed later after conversion to 9a-j.  
 
Table-1: Physicochemical parameter for the synthesized compounds 9a-j and precursors 
 
Code Mol. Formular 
(Mol. Weight)  
M. Pt (oC) Yield 
(%)  
Rf  Colour Elemental Analysis 
% Calcd. (%Found) 
7 C15H15NO4S 
(305.35) 
296-298 91 0.44y offwhite 
powder 
59.00          4.95          4.59 
(58.82)       (5.01)        (4.68) 
8 C17H19NO4S 
(333.40) 
241-243 66 0.53x White 
pellet 
61.24          5.74          4.20 
(61.41)       (5.92)        (4.39) 
9a C21H20N2O3S 
(380.46) 
219-221 86 0.80x White 
powder 
66.29          5.30          7.36  
(66.45)       (5.35)        (7.55) 
9b C21H19N3O5S 
(425.46) 
173-175 87 0.80y Yellow 
pellet 
59.28          4.50          9.88 
(59.47)       (4.69)        (10.04) 
9c C21H19N2O3SCl 
(414.91) 
209-212 74 0.82z White 
powder 
60.79          4.62          6.75   
(60.95)       (4.45)        (6.83)        
9d C25H22N2O3S 
(430.52) 
191-192 65 0.87z Lilac 
powder 
69.75          5.15          6.51 
(69.91)       (4.98)        (6.70) 
9e C15H17N3O3S 
(319.38) 
269-272 54 0.64y White 
powder 
56.41          5.37         13.16 
(56.25)       (5.52)       (12.97) 
9f C21H19N5O7S 
(485.47) 
188-190 82 0.69y Red 
powder 
51.95          3.94        14.43 
(52.09)       (4.04)      (14.60) 
9g C16H18N4O4S 
(362.40) 
208-210 55 0.84x Brown 
crystal 
53.03          5.01        15.46 
(52.91)       (4.93)      (15.63)  
9h C20H26N2O3S 
(374.50) 
Semi solid 89 0.48x Slurry 
cream 
64.14          7.00        7.48 
(63.99)       (6.85)      (7.64) 
9i C21H26N2O3S 
(386.51) 
244-246 63 0.51x Cream 
powder 
65.26          6.78        7.25 
(65.19)       (6.87)      (7.43) 
9j C31H48N2O3S 
(528.79) 
224-227 91 0.58y Powder 
ash 
70.41          9.15        5.30 
(70.55)       (8.97)      (5.50) 
Solvent ratio x = (DCM/Methanol; 9:1), y = (DCM/Hexane; 9:1), z = (DCM/Hexane; 8:2)  
 
The spectroscopic characterization of the synthesized compounds was investigated using infrared, 
ultraviolet, 1H and 13C NMR. The 1H NMR spectra of all synthesized compounds have been analyzed 
in DMSO-d6 over the scan range of 0 to 13 δ ppm. The spectroscopic result of compound 9a was given in 
detail as a representative of the final products 9a-j. The most downfield signal in 9a was 1H singlet of an 
amide at δH 11.08 ppm. A doublet at δH 7.62-7.60 ppm was attributed to 2H aromatic linked to sulfonyl 
group and with a J value of 8.34 Hz, while the doublet assigned at δH 7.45-7.43 ppm was 2H aromatic 
linked to amide moieties and with a coupling constant of 8.00 Hz. All other eleven protons of aromatic 
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resonated as a 5H multiplet at δH 7.27-7.24 ppm, 3H multiplet at δH 7.20-7.18 ppm and 3H multiplet at δH 
7.15-7.12 ppm. These aromatic proton values were consistent with those earlier reported by Kushwaha et 
al.,25 who synthesized and investigated some amide derivatives for their biological activity. The proton of 
NH signal linked CH resonated as a doublet at δH 5.88-5.86 ppm, while that of its CH neighbor was noticed 
as a multiplet at δH 4.31-4.25 ppm. This chemical shift in CH was due to deshielding effect as an inserted 
CH between sulfonamide and amide functionalities. The most upfield signal was that of CH2 linked to 
benzene and they resonated separately as a 1H doublet of doublet each at δH 3.13-3.09 ppm and 3.04-2.99 
ppm respectively. The 13C NMR spectra of all the synthesized compounds have been analyzed in DMSO-
d6 over the scan range of 0 to 200 ppm. The 13C-NMR spectrum was run at 100 MHz using DMSO-d6 and 
compound 9a was observed to have its most downfield signal at 171.3 ppm which was for carbonyl of the 
amide. Eighteen aromatic carbon were found from 145.1 ppm to 115.2 ppm while methane carbon (CH) 
was found at 56.5 ppm in compound 9a. The least signal was that of methylene (CH2) which resonated at 
39.0 ppm. In the overall for targeted products 9a-j, the most deshielded carbon was found in 9g with signal 
at 172.9 ppm which was due to the presence of carbonyl of amide and it fell within the range of the values 
earlier reported by Ajani et al.,26 who synthesized and examined spectroscopic features of some bioactive 
sulfonamide containing motifs. The most shielded carbon atom among the final product was found in 9j 
with chemical shift of 18.5 ppm which depicted the presence of CH3 attached to long aliphatic carbon 
chains. However, it is worthy to note that the chemical shift of C=O of precursor 7 (δc 178.5 ppm) was 
higher than that of all the final products 9a-j (δc 171.1-172.9 ppm), which implied that there was an obvious 
synthetic modification on the COOH of precursor 7 to have led to the final product which was bearing C=O 
of amide.  The careful evaluation of infrared spectral feature of compound 9a revealed that the absorption 
frequency at 3415 cm-1 was for N-H functionality and it was doubly confirmed by the presence of bending 
vibration bands at 1491 cm-1 and C-N functionality at 1073 cm-1. The absorption frequencies at 2930 cm-1 
and 2850 cm-1 were for C-H of aliphatic which was confirmed by the occurrence of CH2 deformation at 
1459 cm-1 which were consistent with an earlier report.30 The absorption frequencies at 1685 cm-1 as well 
as 1610 cm-1 in compounds 9a showed the presence carbonyl of amide and C=C aromatic respectively. The 
two sulfonyl bands were present at 1377 cm-1 and 1140 cm-1. This fell within the range earlier reported by 
Ajani et al.12 for some bioactive sulfonamides. The UV spectrum of 9a was run in methanol and the 
wavelength λmax was recorded in nanometer (nm) alongside with the log εmax. Generally, the electronic 
transition of UV-visible spectra of all synthesized compounds in methanol led to the λmax values from 206 
nm to 593 nm. Specifically speaking for 9a, the first wavelength was observed at 207 nm (Log εmax 5.01) 
which was as a result of π→π* transition peculiar to C=C of the benzene ring. Other transitions were 
observed in the UV spectrum of 9a giving rise to λmax values at 244 nm (Log εmax 5.47), 286 nm (Log εmax 
5.11) and 583 nm (Log εmax 2.00). The bathochromic shift observed at the higher wavelengths between 244 
nm to 583 nm was due to the occurrence of π→n transition that was resulting from the presence of the 
chromophoric moieties and auxochromic group attached to the ring system. The delocalization of their lone 
pairs played a key role in the bathochromic shift occurrence experienced herein. 
            
CONCLUSION 
Based on the results, it can be concluded that the synthesis of the sulfonamide bearing diversified 
carboxamide was successfully achieved. The characterization carried out authenticated the structures of the 
targeted products as envisaged. The technique used herein was found to be efficient and cost-effective for 
the production of the series of new sulfonamide derivatives. The targeted compounds are good candidates 
for further study for antimicrobial investigation and could probably be the potential source of 
chemotherapeutic drugs. 
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